Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 μg/ethinyl estradiol 20 μg

被引:26
作者
Johnson, Julia V.
Grubb, Gary S.
Constantine, Ginger D.
机构
[1] Wyeth Ayerst Res, Womens Hlth, Clin Res Dev, Collegeville, PA 19426 USA
[2] Univ Vermont, Coll Med, Dept Obstet & Gynecol, Burlington, VT 05401 USA
关键词
continuous oral contraceptive; endometrium; ethinyl estradiol; levonorgestrel; safety;
D O I
10.1016/j.contraception.2006.07.009
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Objective: The objective of this study was to evaluate the effect of a continuous daily regimen of levonorgestrel (LNG) 90 mu g/ethinyl estradiol (EE) 20 mu g on endometrial histology. Methods: This was a substudy of a large phase 3 trial conducted in six sites in North America. Healthy and sexually active women aged between 18 and 49 years took LNG 90 mu g/EE 20 pg daily for I year. Results from endometrial biopsies performed at pretreatment baseline and those after at least 6 months of treatment were compared. Results: Of the 146 participants, 93 had a baseline biopsy and completed at least six pill packs. Before treatment, 56 subjects (60%) had an endometrial biopsy with findings classified as "weakly proliferative or proliferative." During the last on-therapy visit, 48 subjects (52%) had an endometrium, categorized as "other," which included primarily an inactive or benign endometrium (n = 42). No hyperplasia or malignancy was observed during the study. Conclusion: The results of a 1-year continuous regimen of LNG 90 mu g/EE 20 mu g were shown to have a good endometrial safety profile. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:23 / 26
页数:4
相关论文
共 10 条
[1]
Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen [J].
Anderson, FD ;
Hait, H ;
Hsiu, J ;
Thompson-Graves, AL ;
Wilborn, WH ;
Willlams, RF .
CONTRACEPTION, 2005, 71 (01) :55-59
[2]
Endometrial histology during use of a low-dose estrogen-desogestrel oral contraceptive with a reduced hormone-free interval [J].
Archer, DF .
CONTRACEPTION, 1999, 60 (03) :151-154
[3]
ARCHER DF, IN PRESS CONTRACEPTI
[4]
Baird DT, 2001, HUM REPROD, V16, P1527
[5]
Coenen C M, 1996, Eur J Contracept Reprod Health Care, V1, P325, DOI 10.3109/13625189609150678
[7]
Kurman RJE, 2002, BLAUSTEINS PATHOLOGY
[8]
Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 μg of ethinyl estradiol on the human endometrium [J].
Lüdicke, F ;
Johannisson, E ;
Helmerhorst, FM ;
Campana, A ;
Foidart, JM ;
Heithecker, R .
FERTILITY AND STERILITY, 2001, 76 (01) :102-107
[9]
Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: A randomized trial [J].
Miller, L ;
Hughes, JP .
OBSTETRICS AND GYNECOLOGY, 2003, 101 (04) :653-661
[10]
An open-label study of the effects of a 24-day regimen of gestodene 60 μg/ethinylestradiol 15 μg on endometrial histological findings in healthy women [J].
Oosterbaan, H. P. .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 1999, 4 :3-8